Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNS NASDAQ:LMAT NASDAQ:LQDA NASDAQ:PRCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAvanos Medical$12.14+0.1%$11.62$9.30▼$24.23$563.30M1.12546,315 shs68,753 shsLMATLeMaitre Vascular$91.14-1.3%$90.69$71.42▼$109.58$2.06B0.79189,597 shs28,044 shsLQDALiquidia Technologies$22.33-2.5%$23.28$9.71▼$29.94$1.91B0.221.86 million shs1.38 million shsPRCTPROCEPT BioRobotics$39.48+2.7%$44.39$36.75▼$103.81$2.19B1.031.02 million shs255,225 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAvanos Medical+1.95%-1.03%+3.97%-1.79%-49.66%LMATLeMaitre Vascular+0.04%-0.09%-8.01%+8.83%+2.59%LQDALiquidia Technologies-3.70%-14.46%-14.68%+66.18%+130.15%PRCTPROCEPT BioRobotics+2.86%+1.21%-6.72%-34.74%-54.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAvanos Medical$12.14+0.1%$11.62$9.30▼$24.23$563.30M1.12546,315 shs68,753 shsLMATLeMaitre Vascular$91.14-1.3%$90.69$71.42▼$109.58$2.06B0.79189,597 shs28,044 shsLQDALiquidia Technologies$22.33-2.5%$23.28$9.71▼$29.94$1.91B0.221.86 million shs1.38 million shsPRCTPROCEPT BioRobotics$39.48+2.7%$44.39$36.75▼$103.81$2.19B1.031.02 million shs255,225 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAvanos Medical+1.95%-1.03%+3.97%-1.79%-49.66%LMATLeMaitre Vascular+0.04%-0.09%-8.01%+8.83%+2.59%LQDALiquidia Technologies-3.70%-14.46%-14.68%+66.18%+130.15%PRCTPROCEPT BioRobotics+2.86%+1.21%-6.72%-34.74%-54.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAvanos Medical 2.00HoldN/AN/ALMATLeMaitre Vascular 2.40Hold$97.607.09% UpsideLQDALiquidia Technologies 3.00Buy$32.1143.81% UpsidePRCTPROCEPT BioRobotics 2.78Moderate Buy$70.0077.30% UpsideCurrent Analyst Ratings BreakdownLatest AVNS, LQDA, LMAT, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/23/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$95.009/16/2025PRCTPROCEPT BioRoboticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/2/2025PRCTPROCEPT BioRoboticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.008/15/2025LQDALiquidia TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$43.008/13/2025LQDALiquidia TechnologiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$33.00 ➝ $41.008/13/2025LQDALiquidia TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$25.00 ➝ $31.008/12/2025AVNSAvanos MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/12/2025LQDALiquidia TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.008/7/2025PRCTPROCEPT BioRoboticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$75.00 ➝ $58.008/7/2025PRCTPROCEPT BioRoboticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$80.00 ➝ $55.008/6/2025LMATLeMaitre VascularCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$92.00 ➝ $95.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAvanos Medical$687.80M0.82$12.14 per share1.00$18.03 per share0.67LMATLeMaitre Vascular$219.86M9.38$2.36 per share38.62$15.00 per share6.08LQDALiquidia Technologies$14M137.31N/AN/A$0.91 per share24.54PRCTPROCEPT BioRobotics$224.50M9.78N/AN/A$7.71 per share5.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAvanos Medical-$392.10M-$10.07N/A7.02N/A-66.89%6.16%4.57%10/29/2025 (Estimated)LMATLeMaitre Vascular$44.04M$2.0644.2442.002.3720.08%13.67%9.14%10/30/2025 (Estimated)LQDALiquidia Technologies-$130.39M-$1.70N/AN/AN/A-732.17%-232.96%-60.81%11/12/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.55N/AN/AN/A-30.60%-23.73%-17.34%10/27/2025 (Estimated)Latest AVNS, LQDA, LMAT, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025LQDALiquidia Technologies-$0.43-$0.49-$0.06-$0.49$3.90 million$8.84 million8/6/2025Q2 2025PRCTPROCEPT BioRobotics-$0.41-$0.35+$0.06-$0.35$75.67 million$79.18 million8/5/2025Q2 2025AVNSAvanos Medical$0.18$0.17-$0.01-$1.66$165.50 million$175.00 million8/5/2025Q2 2025LMATLeMaitre Vascular$0.57$0.60+$0.03$0.60$62.48 million$63.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAvanos MedicalN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.88%N/A38.83%14 YearsLQDALiquidia TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ALatest AVNS, LQDA, LMAT, and PRCT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/30/2025LMATLeMaitre Vascularquarterly$0.200.9%8/21/20258/21/20259/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAvanos Medical0.122.641.58LMATLeMaitre Vascular0.4613.9611.74LQDALiquidia Technologies9.842.492.41PRCTPROCEPT BioRobotics0.139.217.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAvanos Medical95.17%LMATLeMaitre Vascular84.64%LQDALiquidia Technologies64.54%PRCTPROCEPT BioRobotics89.46%Insider OwnershipCompanyInsider OwnershipAVNSAvanos Medical2.64%LMATLeMaitre Vascular9.50%LQDALiquidia Technologies30.10%PRCTPROCEPT BioRobotics17.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAvanos Medical2,22746.40 million45.18 millionOptionableLMATLeMaitre Vascular49022.64 million20.49 millionOptionableLQDALiquidia Technologies5086.09 million60.18 millionOptionablePRCTPROCEPT BioRobotics43055.64 million45.96 millionOptionableAVNS, LQDA, LMAT, and PRCT HeadlinesRecent News About These CompaniesPROCEPT BioRobotics (NASDAQ:PRCT) Hits New 1-Year Low - Should You Sell?September 20 at 5:20 PM | marketbeat.comPROCEPT BioRobotics Updates Executive Severance AgreementsSeptember 18, 2025 | tipranks.comPROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 3.5% - Here's What HappenedSeptember 18, 2025 | marketbeat.comMirador Capital Partners LP Buys New Shares in PROCEPT BioRobotics Corporation $PRCTSeptember 18, 2025 | marketbeat.comHarbor Capital Advisors Inc. Purchases Shares of 41,896 PROCEPT BioRobotics Corporation $PRCTSeptember 18, 2025 | marketbeat.comBTIG Research Reiterates Neutral Rating for PROCEPT BioRobotics (NASDAQ:PRCT)September 18, 2025 | americanbankingnews.comBTIG Research Reaffirms "Neutral" Rating for PROCEPT BioRobotics (NASDAQ:PRCT)September 17, 2025 | marketbeat.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives $73.22 Consensus Price Target from BrokeragesSeptember 15, 2025 | americanbankingnews.comMilitia Capital Partners LP Purchases New Holdings in PROCEPT BioRobotics Corporation $PRCTSeptember 14, 2025 | marketbeat.comPROCEPT BioRobotics Corporation $PRCT Shares Purchased by Osterweis Capital Management Inc.September 14, 2025 | marketbeat.comPROCEPT BioRobotics (NASDAQ:PRCT) Hits New 52-Week Low - Time to Sell?September 13, 2025 | marketbeat.comPROCEPT BioRobotics Corporation $PRCT Shares Bought by Millennium Management LLCSeptember 13, 2025 | marketbeat.comPROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 4.3% - Here's What HappenedSeptember 12, 2025 | marketbeat.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 12, 2025 | marketbeat.comPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 12, 2025 | marketbeat.com50,000 Shares in PROCEPT BioRobotics Corporation $PRCT Purchased by Adage Capital Partners GP L.L.C.September 10, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $38.56 Million Stake in PROCEPT BioRobotics Corporation $PRCTSeptember 9, 2025 | marketbeat.comSandler Capital Management Reduces Stake in PROCEPT BioRobotics Corporation $PRCTSeptember 8, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes $4.19 Million Position in PROCEPT BioRobotics Corporation $PRCTSeptember 8, 2025 | marketbeat.comBaird Financial Group Inc. Acquires 15,880 Shares of PROCEPT BioRobotics Corporation $PRCTSeptember 8, 2025 | marketbeat.comAlliancebernstein L.P. Has $124.89 Million Stock Position in PROCEPT BioRobotics Corporation $PRCTSeptember 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVNS, LQDA, LMAT, and PRCT Company DescriptionsAvanos Medical NYSE:AVNS$12.14 +0.01 (+0.08%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.LeMaitre Vascular NASDAQ:LMAT$91.14 -1.16 (-1.25%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Liquidia Technologies NASDAQ:LQDA$22.33 -0.57 (-2.49%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.PROCEPT BioRobotics NASDAQ:PRCT$39.48 +1.02 (+2.65%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
